Market Risers: 3i Group plc, Antofagasta, AstraZeneca, Burberry Group

Antofagasta Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Shares of 3i Group plc with company EPIC: LON:III has increased 2.1% or 22.75 points during the course of today’s session so far. Investors have remained optimistic during the session. The periods high figure was 1111 and hitting a low of 1086.5. Volume total for shares traded during this period was 379,474 with the average number of shares traded daily being 1,520,433. A 52 week share price high is 1166 which is 84 points difference from the previous close and the 52 week low at 754.6 making a difference of 327.4 points. 3i Group plc now has a 20 SMA of 1112.45 and now the 50 day moving average at 1110.76. This puts the market cap at £10,749.56m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for 3i Group plc being recorded at Tuesday, August 20, 2019 at 12:57:49 PM GMT with the stock price trading at 1104.75 GBX.

The share price for Antofagasta plc found using EPIC: LON:ANTO has increased 2.04% or 16.6 points during the course of today’s session so far. Traders have remained positive while the stock has been in play. Range high for the period has seen 836 meanwhile the session low reached 815. The total volume of shares traded by this point was 597,573 while the daily average number of shares exchanged is 2,708,460. A 52 week share price high is 1026 amounting to 210.6 points difference from the previous days close and putting the 52 week low at 713.2 which is a difference of 102.2 points. Antofagasta plc has a 20 day moving average of 889.7 and now its 50 day moving average now of 898.76. The market capitalisation is now £8,202.33m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Antofagasta plc being recorded at Tuesday, August 20, 2019 at 12:58:15 PM GMT with the stock price trading at 832 GBX.

Shares of AstraZeneca plc with EPIC code: LON:AZN has moved up 1.85% or 135 points throughout today’s trading session so far. Market buyers have stayed positive during the session. The period high was 7434 meanwhile the session low reached 7308. The number of shares traded by this point in time totalled 380,596 while the average shares exchanged is 2,273,677. A 52 week share price high is 7475.15 equating to 194.15 points difference from the previous days close and putting the 52 week low at 5312 which is a variance of 1969 points. AstraZeneca plc has a 20 SMA of 7165.12 and a 50 day MA at 6722.37. The market capitalisation is now £97,288.75m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Tuesday, August 20, 2019 at 12:58:24 PM GMT with the stock price trading at 7416 GBX.

Shares of Burberry Group plc ticker lookup code: LON:BRBY has risen 1.65% or 35 points in today’s trading session so far. Traders have remained optimistic throughout the trading session. The periods high has already touched 2155 dropping as low as 2118.25. The total volume of shares exchanged through this period comes to 260,989 whilst the daily average number of shares exchanged is just 1,830,521. The 52 week high for the share price is 2362 some 245 points difference from the previous days close and the 52 week low at 1618.5 a difference of some 498.5 points. Burberry Group plc now has a 20 SMA of 2237.43 and now its 50 day simple moving average now of 2063.76. The market cap now stands at £8,854.74m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Burberry Group plc being recorded at Tuesday, August 20, 2019 at 12:58:45 PM GMT with the stock price trading at 2152 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

      Search

      Search